<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.9.2" -->
<rss version="0.92">
<channel>
	<title>PCMA</title>
	<link>http://www.pcmanet.org</link>
	<description>PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.  PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.</description>
	<lastBuildDate>Wed, 10 Mar 2010 22:16:30 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>New Survey: Three in Four Enrollees Oppose Legislation to Change FEHBP</title>
		<description><![CDATA[Poll Finds Overwhelming Satisfaction with FEHBP Pharmacy Benefit;
Most Think Bill Would Hurt, Not Help 
(Washington, DC)— Seventy-four percent of those enrolled in the Federal Health Benefits Program (FEHBP) oppose a new effort by Congress to change the program’s prescription drug benefits, according to a new poll released by the Pharmaceutical Care Management Association (PCMA).  
The survey of [...]]]></description>
		<link>http://www.pcmanet.org/new-survey-three-in-four-enrollees-oppose-legislation-to-change-fehbp/</link>
			</item>
	<item>
		<title>Survey of Federal Employees Regarding FEHBP Drug Benefit</title>
		<description><![CDATA[Survey of Federal Employees Regarding FEHBP Drug Benefit
]]></description>
		<link>http://www.pcmanet.org/survey-of-federal-employees-regarding-fehbp-drug-benefit/</link>
			</item>
	<item>
		<title>PCMA: New GAO Report Highlights the Need for Meaningful Biogenerics Reform</title>
		<description><![CDATA[Accelerate Competition to Lower Costs, Increase Access
(Washington, DC)— The Pharmaceutical Care Management Association (PCMA) released the following statement today on a new Government Accountability Office (GAO) report examining specialty-tier prescription drugs in Medicare Part D:
“The high prices of biotech drugs in the new GAO report underscore the importance of creating much-needed competition to lower costs [...]]]></description>
		<link>http://www.pcmanet.org/pcma-new-gao-report-highlights-the-need-for-meaningful-biogenerics-reform/</link>
			</item>
	<item>
		<title>Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans</title>
		<description><![CDATA[PCMA:  Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans 
(Washington, DC)— Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on today’s Federal Workforce, Postal Service, and District of Columbia Subcommittee on House Oversight and Government Reform Committee hearing on the Federal Employees [...]]]></description>
		<link>http://www.pcmanet.org/proposed-overhaul-of-fehbp-pharmacy-benefit-would-undermine-cost-saving-tools-reduce-choices-for-8-million-americans/</link>
			</item>
	<item>
		<title>H.R. 4489, the &#8220;FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act&#8221; &#8212; PCMA Statement for the Record</title>
		<description><![CDATA[Read PCMA Statement for the Record re:  H.R. 4489, the &#8220;FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act&#8221;
Legislative Hearing of the Subcommittee on Federal Workforce, Postal Service, and the District of Columbia
February 23, 2010
]]></description>
		<link>http://www.pcmanet.org/h-r-4489-the-fehbp-prescription-drug-integrity-transparency-and-cost-savings-act-pcma-statement-for-the-record/</link>
			</item>
	<item>
		<title>Pharma Executive Perspectives to be Highlight of Upcoming PBM Summit</title>
		<description><![CDATA[PCMA’s upcoming PBM Summit in Bonita Springs, FL, will feature keynote sessions with Boehringer Ingelheim’s President &#38; CEO Marty Carroll, Allergan President Julian Gangolli, and Bill Marth, President &#38; CEO of Teva North America.
Additionally, PCMA is pleased to announce an exciting session with three of the industry’s leading managed markets executives:

Jim Robinson, Vice President Health [...]]]></description>
		<link>http://www.pcmanet.org/pharma-executive-perspectives-to-be-highlight-of-upcoming-pbm-summit/</link>
			</item>
	<item>
		<title>PCMA Statement:  Wrong Time for Congress to Experiment On The Federal Employees Health Benefits Program</title>
		<description><![CDATA[(Washington, DC)— The Pharmaceutical Care Management Association (PCMA) released the following statement today on new legislation introduced by Congressman Stephen F. Lynch (D-Mass.) — the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) — which would increase prescription drug costs and reduce choices for federal employees:
“Congress has enough on its plate without [...]]]></description>
		<link>http://www.pcmanet.org/pcma-statement-wrong-time-for-congress-to-experiment-on-the-federal-employees-health-benefits-program/</link>
			</item>
	<item>
		<title>New Study: Mail-Service Pharmacies Likely To Improve Prescription Drug Adherence</title>
		<description><![CDATA[(Washington, DC)—Consumers receiving their prescription medications for chronic conditions through a mail-service pharmacy “were more likely to take them as prescribed by their doctors than did patients who obtained them from a local pharmacy,” according to a new study published in the American Journal of Managed Care.  The study is the first to suggest that [...]]]></description>
		<link>http://www.pcmanet.org/new-study-mail-service-pharmacies-likely-to-improve-prescription-drug-adherence/</link>
			</item>
	<item>
		<title>New GAO Study: Lack of Competition Helping Drive ‘Extraordinary’ Brand-Name Drug Price Increases</title>
		<description><![CDATA[ 
PCMA: Accelerate Competition to Lower Costs, Increase Access
(Washington, DC)— A new report from the Government Accountability Office (GAO) that finds “extraordinary price increases” for brand-name drug products from 2000 – 2008 was largely fueled by the “lack of therapeutically equivalent drugs” and “limited competition,” underscores the need for policymakers to promote policies in health reform [...]]]></description>
		<link>http://www.pcmanet.org/new-gao-study-lack-of-competition-helping-drive-%e2%80%98extraordinary%e2%80%99-brand-name-drug-price-increases/</link>
			</item>
	<item>
		<title>PCMA:  Proven PBM Tools Help Drive Historic Slowdown in Prescription Drug Spending</title>
		<description><![CDATA[
Even More Can Be Done, However, to Lower Prescription Drug Costs
(Washington, DC)— Expenditures on prescription drugs increased just 3.2 percent in 2008 – the smallest annual rate of increase in 47 years – according to new data released today by the Centers for Medicare and Medicaid Services (CMS).  This historic low in drug spending growth [...]]]></description>
		<link>http://www.pcmanet.org/pcma-proven-pbm-tools-help-drive-historic-slowdown-in-prescription-drug-spending/</link>
			</item>
</channel>
</rss>
